Clinical Scorecard: Inhibitors of Cyclin-Dependent Kinase 4/6 in Granulosa Cell Tumors: Exploring Their Use with Hormonal Treatments in a Scoping Review
At a Glance
Category
Detail
Condition
Adult Granulosa Cell Tumor (aGCT)
Key Mechanisms
Dysregulation of the cyclin D–CDK4/6–Rb axis contributes to aGCT biology.
Target Population
Patients with recurrent adult granulosa cell tumors.
Care Setting
Oncology and endocrine therapy settings.
Key Highlights
CDK4/6 inhibition may reduce cell viability and tumor growth in GCT models.
Limited clinical evidence suggests disease control in a subset of patients.
Combination of CDK4/6 inhibitors with endocrine therapy is promising.
Guideline-Based Recommendations
Diagnosis
Consider genomic studies for understanding CDK4/6 pathway dysregulation.
Management
Evaluate CDK4/6 inhibitors, particularly abemaciclib, in treatment plans.
Monitoring & Follow-up
Monitor for disease control in patients receiving CDK4/6 inhibitors.
Risks
Limited clinical data on long-term outcomes and side effects.
Patient & Prescribing Data
Patients with recurrent adult granulosa cell tumors.
Combination strategies with endocrine therapy may enhance treatment efficacy.
Clinical Best Practices
Incorporate translational and preclinical findings into clinical decision-making.
Participate in ongoing clinical trials to assess CDK4/6 inhibitors.
